Pyng Medical Corp. Opens U.S. Sales Office
Vancouver, BC – Pyng Medical Corp. (PYT: TSX .V) (the “Company” or “Pyng”) announced today that it has opened its US sales office in Kirkland, Washington to service the growing demand for Pyng’s line of resuscitative care solutions in the United States. The Kirkland office expands the Company’s ability to offer sales and support services to its fast growing base of American customers, distribution partners and prospects.
Pyng is the first company to offer an adult intraosseous infusion device, and continues to lead in resuscitation innovation with simple-to-use, and highly-effective products including FAST1® Intraosseous Infusion System, FAST1™ Intraosseous Infusion Device, T-POD® Pelvic Stabilizer, and MAT® Tourniquet.
“We have seen significant growth in our customer base and level of interest in our resuscitation products and solutions,” said Robert Di Silvio, President and CEO of the Pyng.” Our customers are expanding their commitment to our life-saving devices, and with that commitment, to support their efforts, we are expanding our local resources. The Kirkland office will allow us to deliver superior sales and support to our US customers and to the growing prospect base.”
The new office is located at:
Pyng Medical USA
5400 Carillon Point
Building 5000
4th Floor
Kirkland, Washington 98033
United States
Main tel: 425 576 4133
Main fax: 877 439 2707
About Pyng Medical Corp.
Pyng is the developer and manufacturer of the proprietary, award-winning FAST1™ Intraosseous Infusion System. Pyng was selected in the “2007 TSX Venture 50″ Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1™ has worldwide application for use with hospitals, emergency medical services and military forces.
For More Information
Pyng Medical Corp.
George Dorin, CFO
(604) 303-7964
www.pyng.com
For More Information
George Dorin
Pyng Medical Corp.
(604) 303-7964
www.pyng.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.